drugset / Trial / NCT06153069
Asymptomatic TB With Innovative Modified Short-course Regimens
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.
Timeline
- Start
- 2025-11-21
- Primary completion
- 2027-11
- Completion
- 2028-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ethambutol | Small molecule | — | — |
| Subject | Isoniazid | Small molecule | 300 mg | Oral |
| Subject | Moxifloxacin | Small molecule | 400 mg | Oral |
| Subject | Pyrazinamide | Small molecule | 1000 mg | Oral |
| Subject | Pyrazinamide | Small molecule | 1500 mg | Oral |
| Subject | Pyrazinamide | Small molecule | 2000 mg | Oral |
| Subject | Rifampin | Small molecule | — | — |
| Subject | Rifapentine | Small molecule | 900 mg | Oral |